TransCode Therapeutics, Inc. (RNAZ)
1.81
-0.08
(-4.23%)
USD |
NASDAQ |
Sep 09, 16:00
1.81
0.00 (0.00%)
After-Hours: 16:07
TransCode Therapeutics Shareholders Equity (Quarterly) : 138.36M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 138.36M |
| March 31, 2026 | 144.52M |
| December 31, 2025 | 151.88M |
| September 30, 2025 | 1.426M |
| June 30, 2025 | 6.148M |
| March 31, 2025 | 10.29M |
| December 31, 2024 | -2.019M |
| September 30, 2024 | 1.652M |
| June 30, 2024 | 1.322M |
| March 31, 2024 | 4.584M |
| December 31, 2023 | 1.641M |
| September 30, 2023 | 4.440M |
| June 30, 2023 | 2.092M |
| March 31, 2023 | -0.2368M |
| Date | Value |
|---|---|
| December 31, 2022 | 3.241M |
| September 30, 2022 | 8.244M |
| June 30, 2022 | 12.43M |
| March 31, 2022 | 17.00M |
| December 31, 2021 | 20.40M |
| September 30, 2021 | 23.16M |
| June 30, 2021 | -5.027M |
| March 31, 2021 | -7.832M |
| December 31, 2020 | -3.396M |
| September 30, 2020 | -2.607M |
| June 30, 2020 | |
| March 31, 2020 | |
| December 31, 2019 | -1.098M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 465.53M |
| Oncolytics Biotech, Inc. | -6.167M |
| Sangamo Therapeutics, Inc. | -18.96M |
| Sarepta Therapeutics, Inc. | 1.528B |
| Anixa Biosciences, Inc. | 14.48M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 151.01M |
| Total Liabilities (Quarterly) | 12.65M |
| Debt to Equity Ratio | 0.0047 |
| Current Ratio | 1.971 |
| Net Debt Paydown Yield | -2.08% |